Selank for Sale

Selank for sale listings look interchangeable from the search results, and they stop looking interchangeable roughly two minutes into reading one. The differences are in specific lines that a real seller states and a thin one omits.

This page is that read, in order, with one listing worked through at the end. Everything discussed is research material for laboratory use and not for human consumption.

The listing used as the worked example below is this one.

Selank for sale: the lines a real listing states

Form, stated explicitly. Lyophilised powder in a sealed vial, or a pre-mixed solution in a bottle. These are different products with different handling, and a listing that leaves the format ambiguous is usually hoping you assume the more convenient one. Anyone searching selank vials for sale wants the first; most consumer traffic arrives expecting the second.

Quantity, with a unit. A number of milligrams per vial, not a strength expressed as a percentage or a volume with no concentration attached. A spray priced per bottle with no stated peptide content is not quoting a quantity at all.

A lot number. This is the load-bearing line. Without it, no document on the page can be connected to the vial that would ship, and every other claim floats free.

Testing scope, named rather than implied. Which assays were run, by which laboratory, on which date. Real scope is a list of specific tests. Implied scope is the phrase "third-party tested" printed near a badge graphic.

Storage. A seller who handles cold-chain material states storage conditions, because they affect what has to happen at your end within an hour of delivery.

Legal framing. Research use only, no human consumption, no dosing guidance. A listing that supplies a dosing chart has abandoned the framing under which the sale is being made, which tells you something about the rest of its judgement.

Price mechanics, fully stated. List price, discount and how it applies, quantity tiers, free shipping threshold. A listing that shows a struck-through number and nothing else is showing you a decoration.

The 12.29 mg line, and why it outranks the purity figure

Almost every listing in this market publishes a purity percentage. Very few publish an assayed fill weight, and the second number is the harder one to fake and the more useful one to have.

The Selank certificate for lot 29-01260229, issued by MZ Biolabs in Tucson with an analysis date of 2026-02-07, states a measured quantity of 12.29 mg per vial against a 10 mg label. The vial is overfilled, and the document says so in print.

Consider why that is unusual. Purity is a ratio, and a ratio says nothing about how much is there. A vial can be 99% pure and half empty, and the certificate for a half-empty vial reads beautifully. Fill weight is the number that catches underfilling, which is the cheapest way to shave margin in a market where nobody weighs anything. Publishing it invites a complaint if a future lot comes in low, and most sellers decline the invitation.

The correct way to use it is narrow. It is one lot, measured once. It is not a specification, not a guarantee, and not something to fold into a per-milligram calculation as though every vial were 12.29 mg. What it establishes is a disposition: this seller published a checkable number that could have gone against it.

The same document does the identity work properly too. Selank is a heptapeptide, seven residues in the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, listed on PubChem as CID 11765600 with formula C33H57N11O9 and molecular weight 751.9. The certificate confirms identity by mass spectrometry against an expected monoisotopic mass of 751.43 Da and measures 751.47 Da. Purity by HPLC-UV comes out at 99.32%, with a single minor peak at 0.68%.

The line that is missing, and the document that supplies it

Search that certificate for endotoxin, for LAL, for pyrogen, for sterility. None of them appear. The February report establishes what the powder is and how much of it there is, and it does not address bacterial residue at all.

A listing that showed only that document would be an incomplete listing, and this is where reading the page rather than the linked PDF pays. The product page carries a second certificate, from a different laboratory, presented as images under a heading naming Kovera Labs and batch 29-05260628. That report states purity of 99.371%, net content of 11.86 mg against the 10 mg label, identity by LC-MS, a kinetic chromogenic LAL endotoxin assay to USP Chapter 85 reporting under 0.20 EU/mL against a 0.5 EU/mL limit, a microbial sterility screen returning no growth, and heavy metals screening for arsenic, lead and mercury.

So the honest reading of this listing is not that a test is missing. It is that the two certificates cover different ground, only the narrower one is linked as a PDF, and a buyer who clicks the link and stops has seen the weaker half of the vendor's own evidence.

It matters because FDA's stated concern about this substance is exactly this. On its compounding safety page, current as of 22 April 2026, the agency writes that compounded drugs containing selank acetate "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities". Aggregation and impurities are what purity and identity testing look at. Immunogenicity risk from injected routes is what endotoxin testing looks at. Between the two documents, both halves of that sentence have been addressed, and on the linked one alone, only the first.

What a thin listing omits

A pattern emerges quickly once you have read a dozen. Thin listings omit the lot number and show a certificate anyway. They state a purity figure in body copy with no document behind it. They describe the molecule loosely, and the loose descriptions are often lifted from a different peptide entirely, which is why a listing calling Selank a fifteen-residue or sixteen-residue compound can be dismissed without further reading.

They mention customs in the shipping terms while implying domestic stock elsewhere on the page. They quote a handling window in business days rather than a dispatch cutoff, which is the tell that the vial is not in a warehouse the seller controls. And they carry the claim without the test: sterile written in the description, with nothing in the paperwork that measured it.

A worked read of one listing

Two minutes, applied to the offer above. Form: lyophilised powder, stated. Quantity: 10 mg per vial, stated, and independently assayed at 12.29 mg and 11.86 mg on two published batches. Lot numbers: present, 29-01260229 and 29-05260628, each with a named laboratory and a date. Testing scope: purity and identity on both documents, and endotoxin, sterility and heavy metals on the Kovera one only. Storage: minus 20 degrees Celsius sealed and dry, 4 degrees after reconstitution. Legal framing: research use, no dosing guidance anywhere.

Price mechanics: $47.50 list, reduced from $60.00, and $23.75 with the code PEPTIDEDECK, which is $2.38 per milligram on the label weight. Quantity tiers of 3, 5 and 10 take 3%, 5% and 10% off list, with nothing published saying they stack with the code, so plan on one discount and not two. Free shipping starts at $250, which a single discounted vial does not reach.

Score: strong on everything a listing controls, and weakest on presentation, because the more thorough of its two certificates is the one you cannot click. Reading both is the difference between choosing this vial and assuming things about it.

Where the listing meets the vial

A listing is a claim, and there is exactly one moment when it can be checked against reality: the minute the box is open, before anything else happens.

The label on the vial is the point of contact. It should carry the compound name, the quantity, and a lot number, and that lot number is the one to compare against the certificate you read before ordering. If it matches, the document you checked describes the object in your hand and the whole exercise paid off. If it is a different lot, that is not automatically a problem, because stock rotates and a new batch means new material rather than substituted material. It does mean the certificate you read is now describing a different production run, and the correct response is to go back to the product page and see whether the current lot has a document of its own. A vendor that rotates stock without rotating its published certificates has quietly reverted to the generic-PDF model.

The physical article is also a check in itself. Lyophilised Selank arrives as a white or off-white cake or powder in a small sealed glass vial with a crimped aluminium seal. A vial that arrives already in solution, unsealed, or holding a volume of liquid when the listing described a powder is a listing and a product that do not match, and that is a refund conversation rather than a storage question.

Nothing should imply human use. No dosing card in the box, no instructions for administration, no pharmacy-style label with a patient field. Sellers who include those things have contradicted their own listing, and the contradiction is worth noticing even when the material itself is fine.

Then storage, quickly. The vendor states minus 20 degrees Celsius for the sealed lyophilised vial, kept dry and dark, so the first task on arrival is freezer space rather than paperwork.

Common questions

Keep exploring

The same line-by-line read applied to a peptide whose listings hide behind blend pricing is the BPC-157 question of which format survives the trip. For the version focused on what physically lands on the doorstep, what a MOTS-c order actually delivers covers the unpacking end. And the gap between what an NAD+ listing says and what the vial shows is the closest parallel on published quantities.